Navigation Links
Higher blood sugar levels linked to lower brain function in diabetics, study shows
Date:2/11/2009

WINSTON-SALEM, N.C. Results of a recent study conducted by researchers at Wake Forest University Baptist Medical Center and colleagues show that cognitive functioning abilities drop as average blood sugar levels rise in people with type 2 diabetes.

The study appears in this month's issue of Diabetes Care.

The ongoing Memory in Diabetes (MIND) study, a sub-study of the Action to Control Cardiovascular Risk in Diabetes Trial (ACCORD), found a statistically significant inverse relationship between A1C levels (average blood glucose levels over a period of two to three months) and subjects' scores on four cognitive tests. No association, however, was found between daily blood glucose levels (measured by the fasting plasma glucose test) and test scores.

For the study, researchers at 52 of the 77 ACCORD sites throughout the United States and Canada administered a 30-minute battery of cognitive tests to nearly 3,000 individuals ages 55 years and older.

"The tests used in the study measured several aspects of memory function," said Jeff Williamson, M.D., M.H.S., principal investigator for the study at the Wake Forest clinical site. "For example, we tested one's ability to switch back and forth between memory tasks or to 'multitask,' an important skill for people needing to manage their diabetes."

The results showed that a 1 percent increase in A1C corresponded to slightly lower scores on tests of psychomotor speed, global cognitive function, memory and multiple task management.

"One of the little known complications of type 2 diabetes is memory decline leading to dementia, particularly Alzheimer's dementia," said Williamson, a professor of internal medicine, director of gerontology and geriatrics research, and director of the Roena Kulynych Center for Memory and Cognition Research at Wake Forest Baptist. "This study adds to the growing evidence that poorer blood glucose control is strongly associated with poorer memory function and that these associations can be detected well before a person develops severe memory loss."

Diabetes is a risk factor for mild cognitive impairment, vascular dementia and Alzheimer's disease. Previous studies have shown that people with diabetes are 1.5 times more likely to experience cognitive decline and develop dementia than people without diabetes. The ACCORD-MIND study supports the idea that the brain's chronic exposure to elevated blood glucose levels may be part of the explanation for this phenomenon.

Alternatively, people with impaired cognitive ability have higher A1Cs because they are less compliant in taking medications and controlling their diabetes. The ongoing ACCORD-MIND study, which is overseen by Williamson and a team of Wake Forest Baptist researchers, will test the hypothesis that lowering A1C could result in improved cognitive function.

Meanwhile, "people with type 2 diabetes and their health care providers need to be careful in situations where there is education and teaching about diabetes care, as patients may need a little more time to absorb and process information," Williamson said. "Patients also need to be open to having a family member periodically making sure they are keeping track of managing their diabetes through monitoring, diet, exercise and medication."


'/>"/>

Contact: Jessica Guenzel
jguenzel@wfubmc.edu
336-716-3487
Wake Forest University Baptist Medical Center
Source:Eurekalert

Related medicine news :

1. Mesa Labs Reports Higher Quarterly Sales and Earnings
2. Women who drink lots of soda at higher risk for early kidney disease
3. Dialysis Patients Do Better at Higher Altitudes
4. Higher Blood Sugar Could Impair Thinking
5. Frequent sex and masturbation in 20s and 30s linked to higher prostate cancer risk
6. New Study: Higher DHA Levels Improve Neurodevelopmental Outcomes in Premature Girls
7. An Oral Agent for the Treatment of Moderate to Severe Psoriasis Would Earn a Higher Patient Share in the United States than in Europe
8. Women in Coastal Areas Have Higher Mercury Levels
9. A Stage IV Malignant Melanoma Drug That Increases Overall Survival Would Earn a Higher Patient Share in the U.S. Than in Europe
10. Pediatric MS Tied to Higher Relapse Rates
11. With Depression, Vets Face Higher Suicide Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Harrisburg, PA (PRWEB) , ... December 09, 2016 ... ... concussion education program through the Pennsylvania Cable Network (PCN) during the summer of ... Brain Injury Implementation Grant provided by the United States Department of Health and ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... CURE Media Group, ... and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung ... announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims ... employees that are both engaging and easy to use. Coming off the heels ... company revealed today its plans to roll out new AI-powered self-service enhancements to ...
(Date:12/8/2016)... Dallas, TX (PRWEB) , ... December 08, 2016 , ... ... to continue to be a convenient service for Texas, they are expanding their presence ... will involve a hiring spree that will bring new jobs to the Dallas and ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 2016 Research and Markets has announced ... report to their offering. ... The report forecasts the global optical transceiver market to ... The report covers the present scenario and the growth ... the market size, the report considers the revenue generated from the ...
(Date:12/9/2016)... Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company engaged ... rare diseases, today announced that senior management will participate in a ... at the InterContinental Barclay Hotel in New York City ... About aTyr Pharma ... aTyr Pharma is engaged in the discovery ...
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
Breaking Medicine Technology: